Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    YXT.com

    MCap

    USD127m

    Last close

    USD23.43

    ▲ 20.23 (632.19%)

    Northern Data Group

    MCap

    EUR486m

    Last close

    EUR6.28

    ▲ −1.28 (−16.88%)

    Bodycote

    MCap

    GBP1,572m

    Last close

    GBP9.14

    ▲ −9.00 (−0.98%)

  • Sectors

    Sectors

  • Megatrends

    Megatrends

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

International Stem Cell — Update 2 August 2016

International Stem Cell — Update 2 August 2016

International Stem Cell

Analyst avatar placeholder

Written by

International Stem Cell

First patient dosed in Phase I trial

Clinical update

Pharma & biotech

2 August 2016

Price

US$1.91

Market cap

US$6m

Net cash ($m) at 31 March 2016

1.5

Shares in issue

3.2m

Free float

55%

Code

ISCO

Primary exchange

OTC

Secondary exchange

N/A

Share price performance

%

1m

3m

12m

Abs

(5.7)

(48.8)

(35.4)

Rel (local)

(8.6)

(50.9)

(37.6)

52-week high/low

US$6.5

US$1.8

Business description

International Stem Cell is an early-stage biotechnology company developing therapeutic, biomedical and cosmeceutical applications for its proprietary stem form of pluripotent stem cells – human parthenogenetic stem cells (hpSCs). Its lead candidate is a cell therapy treatment for Parkinson’s disease.

Next events

June quarter results

August 2016

Phase I preliminary data

Q117

Analysts

Maxim Jacobs

+1 646 653 7027

Nathaniel Calloway

+1 646 653 7036

International Stem Cell Corporation is a research client of Edison Investment Research Limited

International Stem Cell announced in July 2016 that it had dosed the first patient in the Phase I dose escalation study examining its neural stem cell product ISC-hpNSC for the treatment of moderate to severe Parkinson’s disease. The study will enrol 12 patients at three dosing regimens with a primary endpoint of safety, but will provide preliminary efficacy data measured at six and 12 months following the treatment.

Year
end

Revenue ($m)

PBT*
($m)

EPS*
($)

DPS
($)

P/E
(x)

Yield
(%)

12/14

7.0

(8.7)

(9.71)

0.0

N/A

N/A

12/15

7.6

(4.6)

(1.29)

0.0

N/A

N/A

12/16e

8.2

(5.5)

(1.73)

0.0

N/A

N/A

12/17e

9.0

(5.8)

(1.83)

0.0

N/A

N/A

Note: *PBT and EPS are normalized, excluding amortization of acquired intangibles, exceptional items and share-based payments.

Optimal dose of cells sought

Patients on the study will be treated with 30m to 70m stem cells, delivered via intracranial injection. The single-arm, open-label study is being conducted at the Royal Melbourne Hospital in Australia. Clinical assessments are scheduled at six and 12 months following surgery, and the data from this trial will be used in the design of a future Phase II trial expected to initiate in late 2017 or 2018.

Trial will provide first evaluation of efficacy

In addition to safety, the trial will also provide physiological and functional assessments of the patients, which will give the first indication of the efficacy of the treatment in humans. Brain function will be directly assessed via PET scan to assess the degree of disease progression. Additionally, patients will be assessed via the six-point Unified Parkinson Disease Rating Scale (UPDRS), a qualitative functional scale of a patient’s mental state, muscle tone and ability to perform daily tasks.

Building on significant primate data

ISC-hpNSC has been previously evaluated in non-human primates, where it was found that the treatment increased the number of dopaminergic nerve fibers in the brain, resulting in an increase in the concentration of free dopamine. Additionally, the animals were assessed via functional assay for Parkinsonian symptoms, and those in the active arm showed a statistically significant improvement over control.

Valuation: $28m or $8.75 per basic share

We have increased our valuation to $28m (from $27m), but have reduced the valuation per basic share to $8.75 (from $9.60). This reflects higher cash ($1.5m vs $0.5m) offset by an increase in the number of shares (3.2m vs 2.8m previously). Otherwise our valuation remains unchanged. There remain approximately 19m in potentially dilutive shares from warrants, options and convertible preferred stock. We maintain that the company will need at least $76m in additional financing before profitability in 2024.

Got stem cells on the brain?

On 28 July 2016, International Stem Cell Corporation announced that it had initiated the Phase I trial of ISC-hpNSC for the treatment of Parkinson’s disease (PD). ISC-hpNSC is the company’s proprietary neural stem cells (NSC) derived from a human parthenogenetic stem cell line (hpSC). The trial is a dose escalation study designed to evaluate the safety of the intracranial injection of between 30m and 70m cells. The trial will also evaluate the treatment for efficacy by monitoring changes in brain function via PET scan, as well as functional assessment via the UPDRS over the course of 12 months. The study will be performed at the Royal Melbourne Hospital in Australia and has a targeted enrolment of 12 moderate to severe PD patients.

The UPDRS is the most common standardized assessment used to monitor the progression and severity of PD in the clinical setting. It comprises six sections including both patient and clinician evaluation of motor function, mood and the ability to perform daily tasks (Exhibit 1).

Exhibit 1: Unified Parkinson Disease Rating Scale

Section

Description

Assessments

1

Mental assessment

Intellectual impairment, thought disorder, depression and initiative

2

Patient scored evaluation of ability to perform daily activities

Hygiene, food preparation, dressing, avoiding falls, speech, tremor etc.

3

Clinician scored motor assessment

Measures of function (tremor, rigidity, posture), functional assessments (ability to rise from a chair, gait, speech) and evaluation of specific muscle groups (fingers, face, legs)

4

Complications associated with therapy

Rate of dyskinesia, assessments of "off" periods, other complications of treatment (nausea, insomnia, etc)

5

The Modified Hoehn Yahr Staging

Global evaluation ranging from no visible signs of disease to wheelchair-bound state

6

Schwab & England Activities of Daily Living Scale

Degree of independence from care givers ranging from completely independent to inability to swallow or perform bowel movements

Source: National Parkinson Foundation

The data from this trial will provide the first assessment of ISC-hpNSC in humans. However, the treatment was previously studied in non-human primates (Exhibit 2). In this model, the treatment successfully increases the number of dopaminergic neurons in the animals’ brains measured post-mortem. This was accompanied by an increase in the concentration of free dopamine (up to approximately 200% dependent on brain region), indicating that the neurons were functional. Finally, the animals treated with ISC-hpNSC showed statistically significant improvement over the control animal on an assessment of Parkinsonian symptoms (ParkScore).

Exhibit 2: ISCO preclinical data

Source: International Stem Cell presentation

PD affects 7-10 million people worldwide with approximately 1.5 million in the US. The most widespread treatment for the disease is the combination of levodopa and carbidopa, which provides the brain with dopamine lost by the death of dopaminergic neurons. The majority of clinical development in the space has been focused on the reformulation of this and other treatment regimens and, to date, no disease-modifying therapies have been approved. A small number of gene and cell therapies focused on changing the course of the disease have entered the clinic (Exhibit 3).

Exhibit 3: Selected clinical-stage cell and gene therapy candidates in PD

Company (originator)

Stage of development

Description

Therapeutic modality

Milestones/comments

Living Cell Technologies

Phase IIa

Choroid plexus cell product that secretes neurotrophins and cerebrospinal fluid (CSF)

Cell therapy

Phase IIb start Q116; NTCELL decreased UPDRS by an average of 16 points after 58 weeks, representing a three- to four-year reversal of neurological deterioration.

International Stem Cell

Phase I

Neuronal cells derived from human parthenogenetic stem cells (hpSC)

Cell therapy: Stem cell

Phase I preliminary data (Q416).

uniQure NV

Phase I

Adeno-associated viral (AAV) vector carrying the glial cell-derived neurotrophic factor (GDNF) gene

Gene therapy: Viral vector: Adeno-associated virus (AAV)

The aim of this clinical trial is to introduce GDNF in a targeted way to the brain to enhance outcomes. NIH research at UCSF with option to license.

Voyager Therapeutics

Phase II

Adeno-associated virus (AAV) serotype 2 encoding the dopa decarboxylase (DDC; AADC) gene injected into the putamen

Gene therapy: Viral vector: Adeno-associated virus (AAV)

Phase Ib data (H216).

Oxford BioMedica

Phase I/II

LentiVector carrying three genes encoding enzymes for dopamine synthesis

Gene therapy: Viral vector: Lentivirus

Preclinical studies in the industry standard in vivo model of Parkinson’s disease have shown that, following a single treatment, almost complete recovery of movement behavior was achieved after five to eight weeks. Therapeutic effect was statistically significant (p<.0.05) after two weeks and was maintained throughout the duration of the preclinical studies, with the latest time point being 44 months.

Source: BioCentury, Edison Investment Research

The announcement that the first patient has been dosed in this trial is consistent with our previously predicted timeline, and we currently expect that the company will be able to progress to a Phase II study in late 2017 or 2018 depending on the safety and efficacy profile discovered in the current trial (preparations may begin at the six-month interim update if early efficacy is seen, or later if the maximum tolerable dose is not reached early); however, we do not expect preliminary data until Q117 (previously Q416). We currently model commercialization of the product in 2024.

Valuation

We are increasing our valuation to $28m (from $27m) based on an increase in cash reported in Q116 following the March 2016 equity offering. However, the valuation per share has been reduced to $8.75 per basic share (from $9.60) based on an increase in the number of shares outstanding. The total number of basic shares increased from 2.8m to 3.2m due to the offering and the subsequent exercise of 290k shares worth of warrants and convertible preferred stock (announced in June 2016). Approximately 19m potentially dilutive shares from warrants, options and preferred stock remain outstanding. Our valuation is otherwise unchanged.

Exhibit 4: rNPV valuation model

Product

Status

Launch

Peak sales ($m)

NPV
($m)

Probability

rNPV
($m)

NPV/share ($/share)

Cosmetic and biomedical business

Commercial

Current

22

29

90%

26

8.21

Parkinson’s disease (royalties at 12% of sales)

Phase I/IIa

2024

2,800

408

7.5%

31

9.68

G&A expense – after tax

100%

(30)

(9.52)

Net cash (at end Q116)

1.5

100%

1.5

0.48

Valuation

 

 

 

438

 

28

8.75

Source: Edison Investment Research estimates

Financials

International Stem Cell reported a loss of $14.6m for Q116, although the majority of this was a non-cash charge for the change in fair value of warrants following the March 2016 offering ($13.4m). We have adjusted our 2016 projections to include this charge and include $19.6m in warrant liability on our balance sheet. The company reported $1.6m in sales from the cosmetic and biomedical business, which translated into a $1.2m operational loss for the quarter. We maintain our forecast of $5.5m in cash losses for 2016, expanding to $15m in 2022 with the advancement of the clinical program. We project financing needs of at least $76m by 2023, which we record as illustrative debt.

Exhibit 5: Financial summary

US$000

2013

2014

2015

2016e

2017e

2018e

Year end 31 December

US GAAP

US GAAP

US GAAP

US GAAP

US GAAP

US GAAP

PROFIT & LOSS

Revenue

 

 

6,150

7,017

7,551

8,167

9,043

9,924

Cost of Sales

(1,643)

(1,921)

(2,056)

(2,205)

(2,442)

(2,580)

Gross Profit

4,507

5,096

5,495

5,962

6,601

7,344

Research and development

(3,560)

(5,386)

(2,707)

(4,000)

(4,000)

(6,000)

EBITDA

 

 

(8,007)

(9,138)

(5,036)

(5,524)

(5,218)

(6,811)

Operating Profit (before amort. and except.)

(7,543)

(8,680)

(4,564)

(5,052)

(4,746)

(6,339)

Intangible Amortization

0

0

0

0

0

0

Exceptionals

0

0

0

(13,401)

0

0

Other

(2,930)

(3,796)

1,929

0

0

0

Operating Profit

(10,473)

(12,476)

(2,635)

(18,453)

(4,746)

(6,339)

Net Interest

(3)

(2)

0

(480)

(1,080)

(1,680)

Profit Before Tax (norm)

 

 

(7,546)

(8,682)

(4,564)

(5,532)

(5,826)

(8,019)

Profit Before Tax (reported)

 

 

(10,476)

(12,478)

(2,635)

(18,933)

(5,826)

(8,019)

Tax

0

0

0

0

0

0

Profit After Tax (norm)

(10,476)

(12,478)

(2,635)

(5,532)

(5,826)

(8,019)

Profit After Tax (reported)

(10,476)

(12,478)

(2,635)

(18,933)

(5,826)

(8,019)

Average Number of Shares Outstanding (m)

0.8

1.3

2.0

3.2

3.2

3.2

EPS - normalized (US$)

 

 

(12.77)

(9.71)

(1.29)

(1.73)

(1.83)

(2.51)

EPS - normalized and fully diluted (US$)

 

(12.77)

(9.71)

(1.29)

(1.73)

(1.83)

(2.51)

EPS - (reported) (US$)

 

 

(12.77)

(9.71)

(1.29)

(5.93)

(1.83)

(2.51)

Dividend per share (US$)

0.0

0.0

0.0

0.0

0.0

0.0

Gross Margin (%)

73.3

72.6

72.8

73.0

73.0

74.0

EBITDA Margin (%)

N/A

N/A

N/A

N/A

N/A

N/A

Operating Margin (before GW and except.) (%)

N/A

N/A

N/A

N/A

N/A

N/A

BALANCE SHEET

Fixed Assets

 

 

3,113

3,563

4,147

4,541

4,953

5,383

Intangible Assets

2,250

2,795

3,223

3,690

4,157

4,624

Tangible Assets

830

714

864

791

736

699

Investments

33

54

60

60

60

60

Current Assets

 

 

4,626

3,616

2,991

6,357

7,745

6,924

Stocks

1,369

1,517

1,348

1,458

1,614

1,772

Debtors

306

453

539

583

645

708

Cash

2,243

1,111

532

3,743

4,914

3,872

Other

708

535

572

572

572

572

Current Liabilities

 

 

(7,021)

(6,858)

(5,544)

(21,553)

(21,680)

(21,807)

Creditors

(7,021)

(6,858)

(5,544)

(21,553)

(21,680)

(21,807)

Short term borrowings

0

0

0

0

0

0

Long Term Liabilities

 

 

0

0

0

(6,000)

(13,500)

(21,000)

Long term borrowings

0

0

0

(6,000)

(13,500)

(21,000)

Other long term liabilities

0

0

0

0

0

0

Net Assets

 

 

718

321

1,594

(16,655)

(22,481)

(30,500)

CASH FLOW

Operating Cash Flow

 

 

(5,635)

(6,413)

(4,120)

(4,645)

(4,366)

(5,960)

Net Interest

(3)

(2)

0

(480)

(1,080)

(1,680)

Tax

0

0

0

0

0

0

Capex

(896)

(988)

(738)

(866)

(884)

(901)

Acquisitions/disposals

0

0

0

0

0

0

Financing

8,123

6,270

1,169

2,500

0

0

Dividends

0

0

0

0

0

0

Net Cash Flow

1,589

(1,133)

(3,689)

(3,492)

(6,330)

(8,541)

Opening net debt/(cash)

 

 

(654)

(2,243)

(1,111)

(532)

2,257

8,586

HP finance leases initiated

0

0

0

0

0

0

Other

0

0

3,110

703

(0)

0

Closing net debt/(cash)

 

 

(2,243)

(1,110)

(532)

2,257

8,586

17,128

Source: Edison Investment Research, company reports

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER
Copyright 2016 Edison Investment Research Limited. All rights reserved. This report has been commissioned by International Stem Cell and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited (“FTSE”) © FTSE 2016. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 9258 1161

Level 25, Aurora Place

88 Phillip St, Sydney

NSW 2000, Australia

Wellington +64 (0)48 948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 9258 1161

Level 25, Aurora Place

88 Phillip St, Sydney

NSW 2000, Australia

Wellington +64 (0)48 948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand

Angle — Update 2 August 2016

Angle

Continue Reading
Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.